Shire Shores Up Rare Disease Portfolio With Amicus Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal valued at up to $440 million would give the U.K. firm three pharmacological chaperone compounds that could compete with Genzyme products in Gaucher, Fabry and Pompe diseases.